Immunomethylomic profiles of long-term head and neck squamous cell carcinoma survivors on immune checkpoint inhibitors

被引:1
|
作者
Lee, Min Kyung [1 ]
Zhang, Ze [1 ]
Sehgal, Kartik [2 ]
Butler, Rondi [3 ,4 ]
Stolrow, Hannah [1 ]
Ramush, Geat [3 ,4 ]
Shirai, Keisuke [5 ]
Koestler, Devin C. [6 ]
Salas, Lucas A. [1 ]
Wiencke, John K. [7 ]
Haddad, Robert [2 ]
Kelsey, Karl T. [3 ,4 ]
Christensen, Brock C. [1 ,8 ,9 ]
机构
[1] Geisel Sch Med Dartmouth, Dept Epidemiol, Lebanon, NH 03755 USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
[3] Brown Univ, Dept Epidemiol, Sch Publ Hlth, Providence, RI 02903 USA
[4] Brown Univ, Dept Pathol & Lab Med, Sch Med, Providence, RI 02903 USA
[5] Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03766 USA
[6] Univ Kansas, Med Ctr, Dept Biostat & Data Sci, Kansas City, KS 66103 USA
[7] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA
[8] Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Lebanon, NH 03755 USA
[9] Geisel Sch Med Dartmouth, Dept Community & Family Med, Lebanon, NH 03755 USA
基金
美国国家卫生研究院;
关键词
DNA methylation; head and neck squamous cell carcinoma; immune checkpoint inhibitors; immune profiles; immunomethylomics; methylation cytometry; MEMORY T-CELLS; DNA METHYLATION;
D O I
10.1080/17501911.2024.2343274
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Aim: This study addresses the challenge of predicting the response of head and neck squamous cell carcinoma (HNSCC) patients to immunotherapy. Methods: Using DNA methylation cytometry, we analyzed the immune profiles of six HNSCC patients who showed a positive response to immunotherapy over a year without disease progression. Results: There was an initial increase in CD8 T memory cells and natural killer cells during the first four cycles of immunotherapy, which then returned to baseline levels after a year. Baseline CD8 T cell levels were lower in HNSCC immunotherapy responders but became similar to those in healthy subjects after immunotherapy. Conclusion: These findings suggest that monitoring fluctuations in immune profiles could potentially identify biomarkers for immunotherapy response in HNSCC patients.
引用
收藏
页码:799 / 807
页数:9
相关论文
共 50 条
  • [1] Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma
    Bila, Michel
    Franken, Amelie
    Van Dessel, Jeroen
    Garip, Melisa
    Meulemans, Jeroen
    Willaert, Robin
    Hoeben, Ann
    Vander Poorten, Vincent
    Clement, Paul M.
    ORAL ONCOLOGY, 2024, 149
  • [2] Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
    Oliva, M.
    Spreafico, A.
    Taberna, M.
    Alemany, L.
    Coburn, B.
    Mesia, R.
    Siu, L. L.
    ANNALS OF ONCOLOGY, 2019, 30 (01) : 57 - 67
  • [3] Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis
    Dang, Shoutao
    Li, Xinyu
    Liu, Heshu
    Zhang, Shuyang
    Li, Wei
    CANCER MEDICINE, 2024, 13 (07):
  • [4] Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials
    Poulose, Jissy Vijo
    Kainickal, Cessal Thommachan
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2022, 13 (05): : 388 - 411
  • [5] Changes in serum lactate dehydrogenase as a prognostic factor in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors
    Lee, Woo Hee
    Takenaka, Yukinori
    Hosokawa, Kiyohito
    Eguchi, Hirotaka
    Suzuki, Masami
    Fukusumi, Takahito
    Suzuki, Motoyuki
    Inohara, Hidenori
    ACTA OTO-LARYNGOLOGICA, 2024, 144 (5-6) : 398 - 403
  • [6] Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck
    Saleh, Khalil
    Auperin, Anne
    Martin, Nicolas
    Borcoman, Edith
    Torossian, Nouritza
    Iacob, Mariana
    Ferrand, Francois-Regis
    Khalife, Nadine
    Baste, Neus
    Guigay, Joel
    Le Tourneau, Christophe
    Daste, Amaury
    Saada-Bouzid, Esma
    Even, Caroline
    EUROPEAN JOURNAL OF CANCER, 2021, 157 : 190 - 197
  • [7] Cerebral Infarction as a Rare Adverse Event of Immune Checkpoint Inhibitors in Patients With Head and Neck Squamous Cell Carcinoma: A Case Series
    Inoue, Takahiro
    Kumai, Takumi
    Ohara, Kenzo
    Takahara, Miki
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [8] Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma
    Manukian, Gregor
    Bar-Ad, Voichita
    Lu, Bo
    Argiris, Athanassios
    Johnson, Jennifer M.
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [9] Immune checkpoint inhibitor use in head and neck squamous cell carcinoma: the current landscape and future perspectives
    Gatfield, Elinor R.
    Tadross, John
    Ince, William
    FUTURE ONCOLOGY, 2024, 20 (23) : 1695 - 1711
  • [10] Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort
    Majd Issa
    Brett G. Klamer
    Nikol Mladkova
    Georgios I. Laliotis
    Vidhya Karivedu
    Priyanka Bhateja
    Chase Byington
    Khaled Dibs
    Xueliang Pan
    Arnab Chakravarti
    John Grecula
    Sachin R. Jhawar
    Darrion Mitchell
    Sujith Baliga
    Matthew Old
    Ricardo L. Carrau
    James W. Rocco
    Dukagjin M. Blakaj
    Marcelo Bonomi
    BMC Cancer, 22